title: Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors in vitro and in vivo.
abstract: The intrinsic activity of the potent dopamine (DA) agonist 4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] was examined in receptor binding assays for the following receptors: DA, alpha-1 and alpha-2 adrenergic, serotonin-1 and -2, neuroleptic, beta adrenergic, anxiolytic, adenosine A-1, gamma-aminobutyric acid, muscarinic and opiate. (+)-PHNO exhibited strong to moderate potencies [IC50 (nanomolars) in parentheses] in binding to DA (24), "neuroleptic" (67), alpha-2 adrenergic (77) and serotonin-1 (277) sites. The pharmacological activity of the naphthoxazine both in vivo and in vitro was contrasted with the known DA agonists apomorphine, pergolide, lisuride and 6-ethyl-9-oxaergoline in tests of DA, alpha-2 adrenergic and serotonergic function. Each compound was examined in vitro in receptor binding assays for interactions with DA, alpha-2 adrenergic, serotonin-1 and serotonin-2 receptors and for alpha-2 adrenergic activity in inhibiting field-stimulated contractions of the vas deferens of the rat. In vivo, alpha-2 adrenergic activity was assayed via measurement of mydriasis after i.v. injections in the rat, whereas serotonin activity was assayed by measuring drug-induced inhibition of 5-hydroxytryptophan accumulation, and DA activity was assessed by quantifying stereotyped behavior after both i.p. and i.v. injections. Selectivity ratios for the DA receptor were derived from effective dose values determined in these tests and demonstrated that only apomorphine was more selective as a DA agonist than (+)-PHNO in vivo. (+)-PHNO was the least active agent at the alpha-2 receptors in the vas deferens and with serotonergic mechanisms in vivo to reduce 5-hydroxytryptophan accumulation.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: G E
authors.initials: GE
authors.lastname: Martin
authors.forename: M
authors.initials: M
authors.lastname: Williams
authors.forename: D J
authors.initials: DJ
authors.lastname: Pettibone
authors.forename: M M
authors.initials: MM
authors.lastname: Zrada
authors.forename: V J
authors.initials: VJ
authors.lastname: Lotti
authors.forename: D A
authors.initials: DA
authors.lastname: Taylor
authors.forename: J H
authors.initials: JH
authors.lastname: Jones
mesh_terms: D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D002415:Cats; D003000:Clonidine / Q000494:pharmacology; D004873:Ergolines / Q000494:pharmacology; D066298:In Vitro Techniques; D008090:Lisuride / Q000494:pharmacology; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009184:Mydriatics; D010078:Oxazines / Q000494:pharmacology*; D010479:Pergolide; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism; D012701:Serotonin / Q000096:biosynthesis; D014649:Vas Deferens / Q000187:drug effects
chemical_list: D004873:Ergolines; D009184:Mydriatics; D010078:Oxazines; D011942:Receptors, Adrenergic, alpha; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; C042631:naxagolide; D010479:Pergolide; D012701:Serotonin; D008090:Lisuride; D003000:Clonidine; D001058:Apomorphine